Activity Preview


AJP CME: October 2017 - Misleading Guidance From Pharmacogenomic Testing

Activity Type:

  • Journal CME

Release Date: 10/1/2017

Expiration Date: 9/30/2019

  • AMA PRA Category 1 Physician: 1
  • Participation: 1

Access Activity


Abstract: In order to better understand the management of cases such as Mr. A’s involving pharmacogenetic testing issues in psychiatry, it is important to have some understanding of the role of such test profiles in clinical cases. Medical genetics is defined as the study of how genes are identified and used for medical applications, including identification of disease or predilection for disease, and for tailoring treatment through targeted drug therapy. Pharmacogenomics, more specifically, is the study of how a person’s genome affects his or her response to certain medications. It must be mentioned that medications can be influenced by a multitude of other factors, including age, sex, ethnicity, liver and kidney function, concomitant medications, and so on. Pharmacogenetics seeks to identify specific genetic polymorphisms in or near the coding region of genes that encode protein structures with which a drug interacts. The identified genetic polymorphisms are then assessed for the putative role in the observed individual variability in the clinical profile of the drug, most notably the drug’s pattern of response and/or side effects.


This activity is only available to AJP CME subscribers.

Don't have a subscription to AJP CME? Subscribe Now! 

  • AJP Subscriber – 12 Month CME Subscription: $150.00
  • Non AJP Subscriber – 12 Month CME Subscription: $300.00

If you have questions about AJP CME subscriptions, please contact

Educational Objective

The participant will interpret evidence for and against the use of pharmacogenetic testing to justify its use in the treatment of mental disorders.

Target Audience

This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.

Estimated Time to Complete

Duration: 1 hour
Begin Date: October 1, 2017
End Date: September 30, 2019

How to Earn Credit

In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit™).  A score of 60% or higher is required to receive credit.


The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Title: Misleading Guidance From Pharmacogenomic Testing

Authors: Tahir Rahman, M.D., David M. Ash, M.D., John Lauriello, M.D., Roshni Rawlani

Affiliations: From the Department of Psychiatry, University of Missouri School of Medicine, Columbia (T.R., D.M.A., J.L., R.R.).

Disclosures: Dr. Lauriello has served on an event monitoring board for a clinical trial through a contract with Janssen Pharmaceutica and the University of Missouri; he has served on advisory panels for Janssen, Otsuka, Reckitt Benckiser, Sunovion, and Teva; and he has overseen clinical research sites for Columbia University sponsored by Sunovion and for Florida Atlantic University sponsored by Otsuka. The other authors report no financial relationships with commercial interests.

Discussion of unapproved or investigational use of products*: No.

*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.

Program Planners

Robert Freedman, M.D. (Editor-in-Chief, AJP); Susan K. Schultz, M.D. (Deputy Editor, AJP); Michael D. Roy (Editorial Director, AJP); Michael A. Pogachar (Online Content Manager, Journals).

Dr. Schultz has received research support from the Alzheimer’s Disease Cooperative Study for projects conducted in partnership with Toyama Chemical Company and in partnership with Eli Lilly and Company. Dr. Freedman, Mr. Roy, and Mr. Pogachar report no financial relationships with commercial interests.

Hardware/Software Requirements

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
  • Flash Player: Adobe Flash Player 10.1+ 
  • Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
  • Operating System: Windows XP+ or Mac OS X 10.4+ 
  • Internet Connection: 1 Mbps or higher
  • Screen Resolution: 1024 x 768 pixels.

Minimum Requirements:

  • Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
  • Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact for questions about this course  |  Contact for technical assistance

Access Activity